Golimumab

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Axial Spondyloarthritis

Conditions

Axial Spondyloarthritis

Trial Timeline

Nov 8, 2017 → Dec 14, 2023

NCT ID

NCT03270501

About Golimumab

Golimumab is a phase 3 stage product being developed by Merck for Axial Spondyloarthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT03270501. Target conditions include Axial Spondyloarthritis.

What happened to similar drugs?

6 of 20 similar drugs in Axial Spondyloarthritis were approved

Approved (6) Terminated (1) Active (14)

🔄Brodalumab + PlaceboKyowa KirinPhase 3

🔄Ixekizumab + PlaceboEli LillyPhase 3

🔄SHR0302 + SHR0302 placeboJiangsu Hengrui MedicinePhase 3

✅AdalimumabAbbVieApproved

🔄Adalimumab + Placebo + Open-label AdalimumabAbbViePhase 3

🔄adalimumab + PlaceboAbbViePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03270501	Phase 3	Completed	Nov 8, 2017	Dec 14, 2023	Axial Spondyloarthritis
NCT03124121	Approved	Completed	Sep 5, 2017	Sep 30, 2019	Ulcerative Colitis
NCT02841176	Pre-clinical	Terminated	Jul 1, 2016	Sep 19, 2017	Psoriatic Arthritis
NCT02318667	Approved	Completed	Feb 27, 2015	Sep 5, 2017	Colitis, Ulcerative
NCT02092285	Approved	Completed	May 9, 2014	May 25, 2016	Ulcerative Colitis
NCT01668004	Approved	Completed	Sep 3, 2012	Apr 30, 2015	Ankylosing Spondylitis

Competing Products

20 competing products in Axial Spondyloarthritis

See all competitors

Product	Company	Stage	Hype Score
SUNPG1622 I dose + Placebo dose	Sun Pharmaceutical	Phase 2	27
Brodalumab + Placebo	Kyowa Kirin	Phase 3	40
Ixekizumab + Placebo	Eli Lilly	Phase 3	40
Ixekizumab + Placebo	Eli Lilly	Phase 3	40
SHR0302 + SHR0302 placebo	Jiangsu Hengrui Medicine	Phase 3	36
SHR-1314	Jiangsu Hengrui Medicine	Phase 1	29
Upadacitinib	AbbVie	Pre-clinical	33
Adalimumab	AbbVie	Approved	35
Adalimumab + Placebo + Open-label Adalimumab	AbbVie	Phase 3	40
adalimumab + Placebo	AbbVie	Phase 3	40
Treatment	Merck	Pre-clinical	66
Tulisokibart + Placebo	Merck	Phase 2	42
Secukinumab 150 milligram [Cosentyx]	Novartis	Approved	39
secukinumab	Novartis	Pre-clinical	26
Secukinumab + Placebo	Novartis	Phase 3	40
Secukinumab + Placebo + Secukinumab	Novartis	Approved	47
Secukinumab + Secukinumab and Placebo	Novartis	Phase 3	40
Secukinumab/Adalimumab-Biosimilar	Novartis	Phase 3	40
Brodalumab 210 mg + Placebo	Amgen	Phase 2	27
Etanercept 25mg + Sulfasalazine	Pfizer	Phase 2	31